Trial Outcomes & Findings for A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate (NCT NCT02706873)

NCT ID: NCT02706873

Last Updated: 2023-07-07

Results Overview

The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 50% response (ACR50) at Week 12. Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 1002 participants
• Primary outcome timeframe: Baseline and Week 12
• Results posted on: 2023-07-07

Participant Flow

Participants were randomized at 236 sites in 43 countries. The study included 2 periods and a Japan sub-study. The global study analysis included participants from Japan, but excluded the upadacitinib 7.5 mg group. The Japan sub-study included all participants from Japan, including the upadacitinib 7.5 mg group.

Participants were randomized in a 1:1:1 ratio to Groups 1, 3, and 4 below, except for participants in Japan who were randomized in a 1:2:1:1 ratio to Groups 1, 2, 3, and 4. Randomization was stratified by geographic region. Efficacy analyses were conducted separately for the Japan sub-study.

Participant milestones

Measure	Methotrexate Group 1 participants received up to 20 mg methotrexate orally per week (15 mg/week in China and Japan) and placebo to upadacitinib once a day (QD) for 48 weeks during Period 1. Participants who did not achieve Clinical Remission (CR) based on clinical disease activity index (CDAI) score (CDAI ≤ 2.8) and did not achieve a ≥ 20% improvement from Baseline in both tender joint count (TJC) and swollen joint count (SJC) at Week 26 were re-randomized in a 1:1 ratio to receive rescue therapy with upadacitinib 15 mg or 30 mg QD (or in a 1:1:1 ratio to receive upadacitinib 7.5 mg, 15 mg, or 30 mg QD for participants in Japan) in addition to methotrexate. In Period 2 (Weeks 48 to 260) participants continued to receive the treatment they were assigned at the end of Period 1.	Upadacitinib 7.5 mg Group 2 participants (Japan only) received 7.5 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1. Participants who did not achieve CR based on CDAI and did not achieve a ≥ 20% improvement from Baseline in both TJC and SJC at Week 26 received rescue treatment with methotrexate 7.5 mg/week in addition to continuing to receive upadacitinib 7.5 mg QD. In Period 2 participants continued to receive the treatment they were assigned at the end of Period 1.	Upadacitinib 15 mg Group 3 participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1. Participants who did not achieve CR based on CDAI and did not achieve a ≥ 20% improvement from Baseline in both TJC and SJC at Week 26 received rescue treatment with methotrexate 10 mg/week (7.5 mg for China and Japan) in addition to continuing to receive upadacitinib 15 mg QD. In Period 2 participants continued to receive the treatment they were assigned at the end of Period 1 up to Week 260.	Upadacitinib 30 mg Group 4 participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1. Participants who did not achieve CR by CDAI and did not achieve a ≥ 20% improvement from Baseline in both TJC and SJC at Week 26 received rescue treatment with methotrexate 10 mg/week (7.5 mg for China and Japan) in addition to continuing to receive upadacitinib 30 mg QD. In Period 2 participants continued to receive the treatment they were assigned at the end of Period 1. Starting with Protocol Amendment 6 participants were switched to receive open-label upadacitinib 15 mg QD.
Period 1 (Weeks 1 to 48) STARTED	315	55	317	315
Period 1 (Weeks 1 to 48) Received Study Drug	314	55	317	314
Period 1 (Weeks 1 to 48) Global Analysis Population	314	0	317	314
Period 1 (Weeks 1 to 48) Japan Sub-study	28	55	27	28
Period 1 (Weeks 1 to 48) Completed Week 24 Study Drug	268	51	290	282
Period 1 (Weeks 1 to 48) Received Combination Rescue Therapy at Week 26	37	3	19	9
Period 1 (Weeks 1 to 48) COMPLETED	256	51	277	271
Period 1 (Weeks 1 to 48) NOT COMPLETED	59	4	40	44
Period 2 (Weeks 48 to 260) STARTED	253	50	275	268
Period 2 (Weeks 48 to 260) Received Study Drug	242	48	273	260
Period 2 (Weeks 48 to 260) COMPLETED	163	40	217	187
Period 2 (Weeks 48 to 260) NOT COMPLETED	90	10	58	81

Reasons for withdrawal

Measure	Methotrexate Group 1 participants received up to 20 mg methotrexate orally per week (15 mg/week in China and Japan) and placebo to upadacitinib once a day (QD) for 48 weeks during Period 1. Participants who did not achieve Clinical Remission (CR) based on clinical disease activity index (CDAI) score (CDAI ≤ 2.8) and did not achieve a ≥ 20% improvement from Baseline in both tender joint count (TJC) and swollen joint count (SJC) at Week 26 were re-randomized in a 1:1 ratio to receive rescue therapy with upadacitinib 15 mg or 30 mg QD (or in a 1:1:1 ratio to receive upadacitinib 7.5 mg, 15 mg, or 30 mg QD for participants in Japan) in addition to methotrexate. In Period 2 (Weeks 48 to 260) participants continued to receive the treatment they were assigned at the end of Period 1.	Upadacitinib 7.5 mg Group 2 participants (Japan only) received 7.5 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1. Participants who did not achieve CR based on CDAI and did not achieve a ≥ 20% improvement from Baseline in both TJC and SJC at Week 26 received rescue treatment with methotrexate 7.5 mg/week in addition to continuing to receive upadacitinib 7.5 mg QD. In Period 2 participants continued to receive the treatment they were assigned at the end of Period 1.	Upadacitinib 15 mg Group 3 participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1. Participants who did not achieve CR based on CDAI and did not achieve a ≥ 20% improvement from Baseline in both TJC and SJC at Week 26 received rescue treatment with methotrexate 10 mg/week (7.5 mg for China and Japan) in addition to continuing to receive upadacitinib 15 mg QD. In Period 2 participants continued to receive the treatment they were assigned at the end of Period 1 up to Week 260.	Upadacitinib 30 mg Group 4 participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1. Participants who did not achieve CR by CDAI and did not achieve a ≥ 20% improvement from Baseline in both TJC and SJC at Week 26 received rescue treatment with methotrexate 10 mg/week (7.5 mg for China and Japan) in addition to continuing to receive upadacitinib 30 mg QD. In Period 2 participants continued to receive the treatment they were assigned at the end of Period 1. Starting with Protocol Amendment 6 participants were switched to receive open-label upadacitinib 15 mg QD.
Period 1 (Weeks 1 to 48) Adverse Event	15	3	18	11
Period 1 (Weeks 1 to 48) Withdrawal by Subject	22	0	12	20
Period 1 (Weeks 1 to 48) Lost to Follow-up	4	0	6	5
Period 1 (Weeks 1 to 48) Lack of Efficacy	12	0	2	4
Period 1 (Weeks 1 to 48) Other	5	1	2	3
Period 1 (Weeks 1 to 48) Not Dosed	1	0	0	1
Period 2 (Weeks 48 to 260) Adverse Event	16	4	11	26
Period 2 (Weeks 48 to 260) Withdrawal by Subject	32	5	23	27
Period 2 (Weeks 48 to 260) Lost to Follow-up	17	0	10	6
Period 2 (Weeks 48 to 260) Lack of Efficacy	11	0	1	1
Period 2 (Weeks 48 to 260) Coronavirus Disease of 2019 (COVID-19) Infection	0	0	0	3
Period 2 (Weeks 48 to 260) COVID-19 Logistic Restrictions	0	0	2	1
Period 2 (Weeks 48 to 260) Other	14	1	11	17

Baseline Characteristics

Participants with available data

Baseline characteristics by cohort

Measure	Methotrexate n=314 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 7.5 mg n=55 Participants Participants received 7.5 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 15 mg n=317 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=314 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Total n=1000 Participants Total of all reporting groups
Age, Continuous	53.3 years STANDARD_DEVIATION 12.89 • n=314 Participants	59.7 years STANDARD_DEVIATION 13.8 • n=55 Participants	51.9 years STANDARD_DEVIATION 12.58 • n=317 Participants	54.9 years STANDARD_DEVIATION 12.58 • n=314 Participants	53.7 years STANDARD_DEVIATION 12.86 • n=1000 Participants
Age, Customized < 40 years	50 Participants n=314 Participants	5 Participants n=55 Participants	60 Participants n=317 Participants	34 Participants n=314 Participants	149 Participants n=1000 Participants
Age, Customized 40 - 65 years	206 Participants n=314 Participants	25 Participants n=55 Participants	204 Participants n=317 Participants	212 Participants n=314 Participants	647 Participants n=1000 Participants
Age, Customized ≥ 65 years	58 Participants n=314 Participants	25 Participants n=55 Participants	53 Participants n=317 Participants	68 Participants n=314 Participants	204 Participants n=1000 Participants
Sex: Female, Male Female	240 Participants n=314 Participants	36 Participants n=55 Participants	241 Participants n=317 Participants	240 Participants n=314 Participants	757 Participants n=1000 Participants
Sex: Female, Male Male	74 Participants n=314 Participants	19 Participants n=55 Participants	76 Participants n=317 Participants	74 Participants n=314 Participants	243 Participants n=1000 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	102 Participants n=314 Participants	0 Participants n=55 Participants	107 Participants n=317 Participants	107 Participants n=314 Participants	316 Participants n=1000 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	212 Participants n=314 Participants	55 Participants n=55 Participants	210 Participants n=317 Participants	207 Participants n=314 Participants	684 Participants n=1000 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=314 Participants	0 Participants n=55 Participants	0 Participants n=317 Participants	0 Participants n=314 Participants	0 Participants n=1000 Participants
Race/Ethnicity, Customized White	256 Participants n=314 Participants	0 Participants n=55 Participants	256 Participants n=317 Participants	254 Participants n=314 Participants	766 Participants n=1000 Participants
Race/Ethnicity, Customized Black or African American	12 Participants n=314 Participants	0 Participants n=55 Participants	8 Participants n=317 Participants	13 Participants n=314 Participants	33 Participants n=1000 Participants
Race/Ethnicity, Customized American Indian/Alaska Native	2 Participants n=314 Participants	0 Participants n=55 Participants	8 Participants n=317 Participants	7 Participants n=314 Participants	17 Participants n=1000 Participants
Race/Ethnicity, Customized Native Hawaiian or other Pacific Islander	2 Participants n=314 Participants	0 Participants n=55 Participants	3 Participants n=317 Participants	1 Participants n=314 Participants	6 Participants n=1000 Participants
Race/Ethnicity, Customized Asian	37 Participants n=314 Participants	55 Participants n=55 Participants	35 Participants n=317 Participants	34 Participants n=314 Participants	161 Participants n=1000 Participants
Race/Ethnicity, Customized Multiple	5 Participants n=314 Participants	0 Participants n=55 Participants	7 Participants n=317 Participants	5 Participants n=314 Participants	17 Participants n=1000 Participants
Geographic Region North America	46 Participants n=314 Participants	0 Participants n=55 Participants	48 Participants n=317 Participants	46 Participants n=314 Participants	140 Participants n=1000 Participants
Geographic Region South/Central America	90 Participants n=314 Participants	0 Participants n=55 Participants	91 Participants n=317 Participants	91 Participants n=314 Participants	272 Participants n=1000 Participants
Geographic Region Western Europe	37 Participants n=314 Participants	0 Participants n=55 Participants	36 Participants n=317 Participants	36 Participants n=314 Participants	109 Participants n=1000 Participants
Geographic Region Eastern Europe	85 Participants n=314 Participants	0 Participants n=55 Participants	87 Participants n=317 Participants	87 Participants n=314 Participants	259 Participants n=1000 Participants
Geographic Region Asia-Japan	28 Participants n=314 Participants	55 Participants n=55 Participants	27 Participants n=317 Participants	28 Participants n=314 Participants	138 Participants n=1000 Participants
Geographic Region Asia - China	1 Participants n=314 Participants	0 Participants n=55 Participants	1 Participants n=317 Participants	1 Participants n=314 Participants	3 Participants n=1000 Participants
Geographic Region Asia - Other	3 Participants n=314 Participants	0 Participants n=55 Participants	4 Participants n=317 Participants	2 Participants n=314 Participants	9 Participants n=1000 Participants
Geographic Region Other	24 Participants n=314 Participants	0 Participants n=55 Participants	23 Participants n=317 Participants	23 Participants n=314 Participants	70 Participants n=1000 Participants
Duration of Rheumatoid Arthritis Diagnosis	2.6 years STANDARD_DEVIATION 5.14 • n=314 Participants	2.3 years STANDARD_DEVIATION 5.77 • n=55 Participants	2.9 years STANDARD_DEVIATION 5.38 • n=317 Participants	2.8 years STANDARD_DEVIATION 5.63 • n=314 Participants	2.7 years STANDARD_DEVIATION 5.40 • n=1000 Participants
Tender Joint Count	26.4 tender joints STANDARD_DEVIATION 16.15 • n=314 Participants	18.0 tender joints STANDARD_DEVIATION 11.75 • n=55 Participants	25.4 tender joints STANDARD_DEVIATION 14.42 • n=317 Participants	25.2 tender joints STANDARD_DEVIATION 14.99 • n=314 Participants	25.3 tender joints STANDARD_DEVIATION 15.12 • n=1000 Participants
Swollen Joint Count	16.9 swollen joints STANDARD_DEVIATION 10.58 • n=314 Participants	14.7 swollen joints STANDARD_DEVIATION 8.24 • n=55 Participants	16.9 swollen joints STANDARD_DEVIATION 10.35 • n=317 Participants	15.7 swollen joints STANDARD_DEVIATION 9.71 • n=314 Participants	16.4 swollen joints STANDARD_DEVIATION 10.13 • n=1000 Participants
Patient's Assessment of Pain	65.7 mm STANDARD_DEVIATION 21.46 • n=314 Participants • Participants with available data	64.1 mm STANDARD_DEVIATION 21.20 • n=55 Participants • Participants with available data	68.4 mm STANDARD_DEVIATION 20.60 • n=317 Participants • Participants with available data	65.3 mm STANDARD_DEVIATION 21.51 • n=311 Participants • Participants with available data	66.3 mm STANDARD_DEVIATION 21.21 • n=997 Participants • Participants with available data
Patient's Global Assessment of Disease Activity	65.8 mm STANDARD_DEVIATION 21.45 • n=314 Participants • Participants with available data	64.1 mm STANDARD_DEVIATION 21.36 • n=55 Participants • Participants with available data	66.6 mm STANDARD_DEVIATION 22.01 • n=317 Participants • Participants with available data	64.9 mm STANDARD_DEVIATION 21.63 • n=311 Participants • Participants with available data	65.7 mm STANDARD_DEVIATION 21.66 • n=997 Participants • Participants with available data
Physician's Global Assessment of Disease Activity	68.7 mm STANDARD_DEVIATION 16.45 • n=299 Participants • Participants with available data	63.3 mm STANDARD_DEVIATION 19.34 • n=54 Participants • Participants with available data	67.1 mm STANDARD_DEVIATION 17.00 • n=301 Participants • Participants with available data	65.3 mm STANDARD_DEVIATION 16.60 • n=304 Participants • Participants with available data	66.8 mm STANDARD_DEVIATION 16.89 • n=958 Participants • Participants with available data
Health Assessment Questionnaire - Disability Index (HAQ-DI)	1.6 units on a scale STANDARD_DEVIATION 0.67 • n=314 Participants • Participants with available data	1.3 units on a scale STANDARD_DEVIATION 0.62 • n=55 Participants • Participants with available data	1.6 units on a scale STANDARD_DEVIATION 0.67 • n=317 Participants • Participants with available data	1.5 units on a scale STANDARD_DEVIATION 0.66 • n=311 Participants • Participants with available data	1.6 units on a scale STANDARD_DEVIATION 0.66 • n=997 Participants • Participants with available data
High-sensitivity C-reactive Protein (hsCRP)	21.2 mg/L STANDARD_DEVIATION 22.05 • n=314 Participants	18.5 mg/L STANDARD_DEVIATION 17.55 • n=55 Participants	23.0 mg/L STANDARD_DEVIATION 27.37 • n=317 Participants	19.4 mg/L STANDARD_DEVIATION 22.59 • n=314 Participants	21.0 mg/L STANDARD_DEVIATION 23.84 • n=1000 Participants
Disease Activity Score 28 Based on CRP (DAS28[CRP])	5.9 units on a scale STANDARD_DEVIATION 0.97 • n=314 Participants • Participants with available data	5.5 units on a scale STANDARD_DEVIATION 0.90 • n=55 Participants • Participants with available data	5.9 units on a scale STANDARD_DEVIATION 0.97 • n=317 Participants • Participants with available data	5.8 units on a scale STANDARD_DEVIATION 1.02 • n=311 Participants • Participants with available data	5.8 units on a scale STANDARD_DEVIATION 0.99 • n=997 Participants • Participants with available data
Modified Total Sharp Score (mTSS)	13.3 units on a scale STANDARD_DEVIATION 30.55 • n=309 Participants • Participants with available data	15.9 units on a scale STANDARD_DEVIATION 39.10 • n=55 Participants • Participants with available data	18.1 units on a scale STANDARD_DEVIATION 38.15 • n=309 Participants • Participants with available data	17.2 units on a scale STANDARD_DEVIATION 38.25 • n=309 Participants • Participants with available data	16.1 units on a scale STANDARD_DEVIATION 36.02 • n=982 Participants • Participants with available data

PRIMARY outcome

Timeframe: Baseline and Week 12

Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders. The global analysis includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 50% response (ACR50) at Week 12. Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:

1. ≥ 50% improvement in 68-tender joint count;

2. ≥ 50% improvement in 66-swollen joint count; and

3. ≥ 50% improvement in at least 3 of the 5 following parameters:

• Physician global assessment of disease activity
• Patient global assessment of disease activity
• Patient assessment of pain
• Health Assessment Questionnaire - Disability Index (HAQ-DI)
• High-sensitivity C-reactive protein (hsCRP).

Outcome measures

Measure	Methotrexate n=314 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=317 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=314 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 - Global Analysis	28.3 percentage of participants Interval 23.4 to 33.3	52.1 percentage of participants Interval 46.6 to 57.5	56.4 percentage of participants Interval 50.9 to 61.9	—

PRIMARY outcome

Timeframe: Week 24

Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 24 or for whom DAS28 data were missing at Week 24 were considered non-responders. The global analysis includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was clinical remission, based on a Disease Activity Score 28 (DAS28)-CRP score of < 2.6 at Week 24.

The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.

A DAS28 score less than 2.6 indicates clinical remission.

Outcome measures

Measure	Methotrexate n=314 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=317 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=314 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 24 - Global Analysis	18.5 percentage of participants Interval 14.2 to 22.8	48.3 percentage of participants Interval 42.8 to 53.8	50.0 percentage of participants Interval 44.5 to 55.5	—

PRIMARY outcome

Timeframe: Baseline and Week 12

Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders. The global analysis includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

The primary endpoint for Japan/Pharmaceuticals and Medical Devices Agency (PMDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:

1. ≥ 20% improvement in 68-tender joint count;

2. ≥ 20% improvement in 66-swollen joint count; and

3. ≥ 20% improvement in at least 3 of the 5 following parameters:

• Physician global assessment of disease activity
• Patient global assessment of disease activity
• Patient assessment of pain
• Health Assessment Questionnaire - Disability Index (HAQ-DI)
• High-sensitivity C-reactive protein (hsCRP).

Outcome measures

Measure	Methotrexate n=314 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=317 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=314 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 - Global Analysis	54.1 percentage of participants Interval 48.6 to 59.7	75.7 percentage of participants Interval 71.0 to 80.4	77.1 percentage of participants Interval 72.4 to 81.7	—

PRIMARY outcome

Timeframe: Baseline to Week 24

Population: Full analysis set participants with available data at Baseline; linear extrapolation was used for participants who discontinued prior to Week 24 or for whom x-ray data were missing at Week 24. The global analysis population includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

The second primary endpoint for Japan/PMDA regulatory purposes was change from baseline in mTSS at Week 24.

The mTSS measures the level of joint damage from radiographs of the hands and feet. Joint erosion and joint space narrowing (JSN) were assessed by two independent, blinded readers.

Joint erosion was assessed in 16 joints in each hand/wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 280 (worst).

JSN was assessed in 15 joints of each hand and wrist, and 6 joints of each foot, including subluxation, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 168 (worst).

The mTSS is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 448 (worst). A change from Baseline greater than 0 indicates progression.

Outcome measures

Measure	Methotrexate n=264 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=279 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=270 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 24 - Global Analysis	0.67 units on a scale Interval 0.43 to 0.9	0.14 units on a scale Interval -0.09 to 0.37	0.07 units on a scale Interval -0.16 to 0.31	—

SECONDARY outcome

Timeframe: Baseline to Week 12

Population: Full analysis set participants with available data at Baseline; multiple imputation was used for missing post-baseline data. The global analysis population includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.

Outcome measures

Measure	Methotrexate n=312 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=317 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=310 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Change From Baseline in DAS28 (CRP) at Week 12 - Global Analysis	-1.85 scores on a scale Interval -2.0 to -1.69	-2.73 scores on a scale Interval -2.87 to -2.58	-2.85 scores on a scale Interval -3.0 to -2.7	—

SECONDARY outcome

Timeframe: Baseline to week 12

Population: Full analysis set participants with available data at Baseline; multiple imputation was used for missing data. The global analysis population includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.

A negative change from Baseline in the overall score indicates improvement.

Outcome measures

Measure	Methotrexate n=313 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=317 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=310 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 - Global Analysis	-0.49 scores on a scale Interval -0.55 to -0.42	-0.83 scores on a scale Interval -0.9 to -0.76	-0.86 scores on a scale Interval -0.93 to -0.79	—

SECONDARY outcome

Timeframe: Week 12

Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom DAS28 data were missing at Week 12 were considered non-responders. The global analysis population includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

The DAS28(CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.

A DAS28(CRP) score less than or equal to 3.2 indicates low disease activity.

Outcome measures

Measure	Methotrexate n=314 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=317 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=314 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 - Global Analysis	28.3 percentage of participants Interval 23.4 to 33.3	53.3 percentage of participants Interval 47.8 to 58.8	54.8 percentage of participants Interval 49.3 to 60.3	—

SECONDARY outcome

Timeframe: Baseline to week 12

Population: Full analysis set participants with available data at Baseline; multiple imputation was used for missing data. The global analysis population includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).

The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.

Outcome measures

Measure	Methotrexate n=311 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=315 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=311 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12 - Global Analysis	5.74 scores on a scale Interval 4.84 to 6.64	9.99 scores on a scale Interval 9.11 to 10.88	10.08 scores on a scale Interval 9.19 to 10.98	—

SECONDARY outcome

Timeframe: Baseline to Week 24

Population: Full analysis set participants with available data at Baseline; multiple imputation was used for missing post-baseline data. The global analysis population includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.

Outcome measures

Measure	Methotrexate n=312 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=317 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=310 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Change From Baseline in DAS28 (CRP) at Week 24 - Global Analysis	-2.15 scores on a scale Interval -2.31 to -1.99	-3.07 scores on a scale Interval -3.21 to -2.92	-3.34 scores on a scale Interval -3.49 to -3.19	—

SECONDARY outcome

Timeframe: Baseline to Week 24

Population: Full analysis set participants with available data at Baseline; multiple imputation was used for missing data. The global analysis population includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.

A negative change from Baseline in the overall score indicates improvement.

Outcome measures

Measure	Methotrexate n=313 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=317 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=310 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24 - Global Analysis	-0.60 scores on a scale Interval -0.67 to -0.52	-0.87 scores on a scale Interval -0.94 to -0.8	-0.91 scores on a scale Interval -0.98 to -0.84	—

SECONDARY outcome

Timeframe: Baseline and Week 24

Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 24 or for whom ACR data were missing at Week 24 were considered non-responders. The global analysis population includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:

1. ≥ 50% improvement in 68-tender joint count;

2. ≥ 50% improvement in 66-swollen joint count; and

3. ≥ 50% improvement in at least 3 of the 5 following parameters:

• Physician global assessment of disease activity
• Patient global assessment of disease activity
• Patient assessment of pain
• Health Assessment Questionnaire - Disability Index (HAQ-DI)
• High-sensitivity C-reactive protein (hsCRP).

Outcome measures

Measure	Methotrexate n=314 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=317 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=314 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants With an ACR50 Response at Week 24 - Global Analysis	33.4 percentage of participants Interval 28.2 to 38.7	60.3 percentage of participants Interval 54.9 to 65.6	65.6 percentage of participants Interval 60.4 to 70.9	—

SECONDARY outcome

Timeframe: Week 24

Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 24 or for whom DAS28 data were missing at Week 24 were considered non-responders. The global analysis population includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

The DAS28(CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.

A DAS28(CRP) score less than or equal to 3.2 indicates low disease activity.

Outcome measures

Measure	Methotrexate n=314 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=317 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=314 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 24 - Global Analysis	32.2 percentage of participants Interval 27.0 to 37.3	59.9 percentage of participants Interval 54.5 to 65.3	65.0 percentage of participants Interval 59.7 to 70.2	—

SECONDARY outcome

Timeframe: Baseline to Week 24

Population: Full analysis set participants with available data at Baseline; multiple imputation was used for missing data. The global analysis population includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).

The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.

Outcome measures

Measure	Methotrexate n=313 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=315 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=312 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 24 - Global Analysis	6.97 scores on a scale Interval 6.03 to 7.91	10.70 scores on a scale Interval 9.76 to 11.63	11.39 scores on a scale Interval 10.42 to 12.36	—

SECONDARY outcome

Timeframe: Week 24

Population: Full analysis set participants with available data at Baseline; linear extrapolation was used for participants who discontinued prior to Week 24 or for whom x-ray data were missing at Week 24. The global analysis population includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

No radiographic progression is defined as a change from Baseline in mTSS ≤ 0. The mTSS measures the level of joint damage from radiographs of the hands and feet. Joint erosion and joint space narrowing (JSN) were assessed by two independent, blinded readers.

Joint erosion severity was assessed in 16 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 280 (worst).

Joint space narrowing (JSN) was assessed in 15 joints of each hand and wrist, and 6 joints of each foot, including subluxation, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 168 (worst).

The mTSS is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 448 (worst).

Outcome measures

Measure	Methotrexate n=264 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=279 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=270 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants With No Radiographic Progression at Week 24 - Global Analysis	77.7 percentage of participants Interval 72.6 to 82.7	87.5 percentage of participants Interval 83.6 to 91.3	89.3 percentage of participants Interval 85.6 to 93.0	—

SECONDARY outcome

Timeframe: Baseline and Week 12

Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders. The global analysis population includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria:

1. ≥ 70% improvement in 68-tender joint count;

2. ≥ 70% improvement in 66-swollen joint count; and

3. ≥ 70% improvement in at least 3 of the 5 following parameters:

• Physician global assessment of disease activity
• Patient global assessment of disease activity
• Patient assessment of pain
• Health Assessment Questionnaire - Disability Index (HAQ-DI)
• High-sensitivity C-reactive protein (hsCRP).

Outcome measures

Measure	Methotrexate n=314 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=317 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=314 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 - Global Analysis	14.0 percentage of participants Interval 10.2 to 17.9	32.5 percentage of participants Interval 27.3 to 37.6	36.9 percentage of participants Interval 31.6 to 42.3	—

SECONDARY outcome

Timeframe: Baseline and Week 24

Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 24 or for whom ACR data were missing at Week 24 were considered non-responders. The global analysis population includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:

1. ≥ 20% improvement in 68-tender joint count;

2. ≥ 20% improvement in 66-swollen joint count; and

3. ≥ 20% improvement in at least 3 of the 5 following parameters:

• Physician global assessment of disease activity
• Patient global assessment of disease activity
• Patient assessment of pain
• Health Assessment Questionnaire - Disability Index (HAQ-DI)
• High-sensitivity C-reactive protein (hsCRP).

Outcome measures

Measure	Methotrexate n=314 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=317 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=314 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants With an ACR20 Response at Week 24 - Global Analysis	58.6 percentage of participants Interval 53.2 to 64.0	78.9 percentage of participants Interval 74.4 to 83.4	78.0 percentage of participants Interval 73.4 to 82.6	—

SECONDARY outcome

Timeframe: Baseline and Week 24

Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 24 or for whom ACR data were missing at Week 24 were considered non-responders. The global analysis population includes participants enrolled under the methotrexate and upadacitinib 15 mg and 30 mg treatment groups.

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria:

1. ≥ 70% improvement in 68-tender joint count;

2. ≥ 70% improvement in 66-swollen joint count; and

3. ≥ 70% improvement in at least 3 of the 5 following parameters:

• Physician global assessment of disease activity
• Patient global assessment of disease activity
• Patient assessment of pain
• Health Assessment Questionnaire - Disability Index (HAQ-DI)
• High-sensitivity C-reactive protein (hsCRP).

Outcome measures

Measure	Methotrexate n=314 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=317 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=314 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants With an ACR70 Response at Week 24 - Global Analysis	18.5 percentage of participants Interval 14.2 to 22.8	44.5 percentage of participants Interval 39.0 to 49.9	49.7 percentage of participants Interval 44.2 to 55.2	—

SECONDARY outcome

Timeframe: Baseline and Week 12

Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders. The Japan sub-study analysis includes participants enrolled in Japan under the methotrexate and upadacitinib 7.5 mg, 15 mg, and 30 mg treatment groups.

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:

1. ≥ 20% improvement in 68-tender joint count;

2. ≥ 20% improvement in 66-swollen joint count; and

3. ≥ 20% improvement in at least 3 of the 5 following parameters:

• Physician global assessment of disease activity
• Patient global assessment of disease activity
• Patient assessment of pain
• Health Assessment Questionnaire - Disability Index (HAQ-DI)
• High-sensitivity C-reactive protein (hsCRP).

Outcome measures

Measure	Methotrexate n=28 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=55 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=27 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=28 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants With an ACR20 Response at Week 12 - Japan Sub-study	57.1 percentage of participants Interval 38.8 to 75.5	85.5 percentage of participants Interval 76.1 to 94.8	85.2 percentage of participants Interval 71.8 to 98.6	78.6 percentage of participants Interval 63.4 to 93.8

SECONDARY outcome

Timeframe: Baseline and Week 12

Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders. The Japan sub-study analysis includes participants enrolled in Japan under the methotrexate and upadacitinib 7.5 mg, 15 mg, and 30 mg treatment groups.

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:

1. ≥ 50% improvement in 68-tender joint count;

2. ≥ 50% improvement in 66-swollen joint count; and

3. ≥ 50% improvement in at least 3 of the 5 following parameters:

• Physician global assessment of disease activity
• Patient global assessment of disease activity
• Patient assessment of pain
• Health Assessment Questionnaire - Disability Index (HAQ-DI)
• High-sensitivity C-reactive protein (hsCRP).

Outcome measures

Measure	Methotrexate n=28 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=55 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=27 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=28 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants With an ACR50 Response at Week 12 - Japan Sub-study	21.4 percentage of participants Interval 6.2 to 36.6	60.0 percentage of participants Interval 47.1 to 72.9	66.7 percentage of participants Interval 48.9 to 84.4	71.4 percentage of participants Interval 54.7 to 88.2

SECONDARY outcome

Timeframe: Baseline and Week 12

Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders. The Japan sub-study analysis includes participants enrolled in Japan under the methotrexate and upadacitinib 7.5 mg, 15 mg, and 30 mg treatment groups.

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria:

1. ≥ 70% improvement in 68-tender joint count;

2. ≥ 70% improvement in 66-swollen joint count; and

3. ≥ 70% improvement in at least 3 of the 5 following parameters:

• Physician global assessment of disease activity
• Patient global assessment of disease activity
• Patient assessment of pain
• Health Assessment Questionnaire - Disability Index (HAQ-DI)
• High-sensitivity C-reactive protein (hsCRP).

Outcome measures

Measure	Methotrexate n=28 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=55 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=27 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=28 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants With an ACR70 Response at Week 12 - Japan Sub-study	0.0 percentage of participants Interval 0.0 to 0.0	34.5 percentage of participants Interval 22.0 to 47.1	51.9 percentage of participants Interval 33.0 to 70.7	64.3 percentage of participants Interval 46.5 to 82.0

SECONDARY outcome

Timeframe: Baseline to Week 12

Population: Full analysis set participants with available data at Baseline; multiple imputation was used for missing post-baseline data. The Japan sub-study analysis includes participants enrolled in Japan under the methotrexate and upadacitinib 7.5 mg, 15 mg, and 30 mg treatment groups.

The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.

Outcome measures

Measure	Methotrexate n=28 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=55 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=27 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=28 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Change From Baseline in DAS28 (CRP) at Week 12 - Japan Sub-study	-1.42 scores on a scale Interval -1.82 to -1.03	-2.86 scores on a scale Interval -3.14 to -2.58	-3.28 scores on a scale Interval -3.68 to -2.89	-3.34 scores on a scale Interval -3.74 to -2.95

SECONDARY outcome

Timeframe: Baseline to week 12

Population: Full analysis set participants with available data at Baseline; multiple imputation was used for missing data. The Japan sub-study analysis includes participants enrolled in Japan under the methotrexate and upadacitinib 7.5 mg, 15 mg, and 30 mg treatment groups.

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.

A negative change from Baseline in the overall score indicates improvement.

Outcome measures

Measure	Methotrexate n=28 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=55 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=27 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=28 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 - Japan Sub-study	-0.20 scores on a scale Interval -0.37 to -0.04	-0.75 scores on a scale Interval -0.86 to -0.63	-0.95 scores on a scale Interval -1.12 to -0.78	-0.95 scores on a scale Interval -1.12 to -0.79

SECONDARY outcome

Timeframe: Baseline to Week 12

Population: Full analysis set participants with available data at Baseline; multiple imputation was used for missing data. The Japan sub-study analysis includes participants enrolled in Japan under the methotrexate and upadacitinib 7.5 mg, 15 mg, and 30 mg treatment groups.

The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).

The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.

Outcome measures

Measure	Methotrexate n=28 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=55 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=27 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=28 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12 - Japan Sub-study	2.87 scores on a scale Interval 0.56 to 5.18	8.84 scores on a scale Interval 7.18 to 10.5	10.79 scores on a scale Interval 8.48 to 13.09	9.63 scores on a scale Interval 7.13 to 12.13

SECONDARY outcome

Timeframe: Week 12

Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom DAS28 data were missing at Week 12 were considered non-responders. The Japan sub-study analysis includes participants enrolled in Japan under the methotrexate and upadacitinib 7.5 mg, 15 mg, and 30 mg treatment groups.

The DAS28(CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.

A DAS28(CRP) score less than or equal to 3.2 indicates low disease activity.

Outcome measures

Measure	Methotrexate n=28 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=55 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=27 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=28 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 - Japan Sub-study	17.9 percentage of participants Interval 3.7 to 32.0	69.1 percentage of participants Interval 56.9 to 81.3	77.8 percentage of participants Interval 62.1 to 93.5	78.6 percentage of participants Interval 63.4 to 93.8

SECONDARY outcome

Timeframe: Week 24

Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom DAS28 data were missing at Week 12 were considered non-responders. The Japan sub-study analysis includes participants enrolled in Japan under the methotrexate and upadacitinib 7.5 mg, 15 mg, and 30 mg treatment groups.

The DAS28(CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.

A DAS28 score less than 2.6 indicates clinical remission.

Outcome measures

Measure	Methotrexate n=28 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=55 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=27 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=28 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 24 - Japan Sub-study	17.9 percentage of participants Interval 3.7 to 32.0	67.3 percentage of participants Interval 54.9 to 79.7	70.4 percentage of participants Interval 53.1 to 87.6	82.1 percentage of participants Interval 68.0 to 96.3

SECONDARY outcome

Timeframe: Baseline to Week 24

Population: Full analysis set participants with available data at Baseline; linear extrapolation was used for participants who discontinued prior to Week 24 or for whom x-ray data were missing at Week 24. The Japan sub-study analysis includes participants enrolled in Japan under the methotrexate and upadacitinib 7.5 mg, 15 mg, and 30 mg treatment groups.

The mTSS measures the level of joint damage from radiographs of the hands and feet. Joint erosion and joint space narrowing (JSN) were assessed by two independent, blinded readers.

Joint erosion was assessed in 16 joints in each hand/wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 280 (worst).

JSN was assessed in 15 joints of each hand and wrist, and 6 joints of each foot, including subluxation, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 168 (worst).

The mTSS is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 448 (worst). A change from Baseline greater than 0 indicates progression.

Outcome measures

Measure	Methotrexate n=26 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=51 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=26 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=24 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 24 - Japan Sub-study	2.64 units on a scale Interval 1.19 to 4.09	0.95 units on a scale Interval -0.09 to 1.98	0.24 units on a scale Interval -1.21 to 1.69	0.19 units on a scale Interval -1.31 to 1.7

SECONDARY outcome

Timeframe: Week 24

Population: Full analysis set participants with available data at Baseline; linear extrapolation was used for participants who discontinued prior to Week 24 or for whom x-ray data were missing at Week 24. The Japan sub-study analysis includes participants enrolled in Japan under the methotrexate and upadacitinib 7.5 mg, 15 mg, and 30 mg treatment groups.

No radiographic progression is defined as a change from Baseline in mTSS ≤ 0. The mTSS measures the level of joint damage from radiographs of the hands and feet. Joint erosion and joint space narrowing (JSN) were assessed by two independent, blinded readers.

Joint erosion severity was assessed in 16 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 280 (worst).

Joint space narrowing (JSN) was assessed in 15 joints of each hand and wrist, and 6 joints of each foot, including subluxation, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 168 (worst).

The mTSS is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 448 (worst).

Outcome measures

Measure	Methotrexate n=26 Participants Participants received up to 20 mg methotrexate orally per week and placebo to upadacitinib once a day for 48 weeks during Period 1.	Upadacitinib 15 mg n=51 Participants Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=26 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.	Upadacitinib 30 mg n=24 Participants Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 48 weeks in Period 1.
Percentage of Participants With No Radiographic Progression at Week 24 - Japan Sub-study	46.2 percentage of participants Interval 27.0 to 65.3	82.4 percentage of participants Interval 71.9 to 92.8	80.8 percentage of participants Interval 65.6 to 95.9	79.2 percentage of participants Interval 62.9 to 95.4

Adverse Events

Weeks 1-24: Methotrexate Monotherapy

Serious events: 13 serious events

Other events: 159 other events

Deaths: 1 deaths

Weeks 1-24: Upadacitinib 7.5 mg Monotherapy

Serious events: 5 serious events

Other events: 38 other events

Deaths: 0 deaths

Weeks 1-24: Upadacitinib 15 mg Monotherapy

Serious events: 16 serious events

Other events: 169 other events

Deaths: 2 deaths

Weeks 1-24: Upadacitinib 30 mg Monotherapy

Serious events: 20 serious events

Other events: 174 other events

Deaths: 3 deaths

Weeks 1-260: Methotrexate Monotherapy

Serious events: 49 serious events

Other events: 234 other events

Deaths: 8 deaths

Weeks 1-260: Upadacitinib 7.5 mg Monotherapy

Serious events: 13 serious events

Other events: 52 other events

Deaths: 1 deaths

Weeks 1-260: Upadacitinib 15 mg Monotherapy

Serious events: 68 serious events

Other events: 242 other events

Deaths: 6 deaths

Weeks 1-260/Switch: Upadacitinib 30 mg Monotherapy

Serious events: 71 serious events

Other events: 256 other events

Deaths: 9 deaths

Weeks 1-260: Any Upadacitinib 7.5 mg

Serious events: 15 serious events

Other events: 55 other events

Deaths: 1 deaths

Weeks 1-260: Any Upadacitinib 15 mg

Serious events: 88 serious events

Other events: 272 other events

Deaths: 6 deaths

Weeks 1-260/Switch: Any Upadacitinib 30 mg

Serious events: 79 serious events

Other events: 277 other events

Deaths: 10 deaths

After Switch: Upadacitinib 15 mg Monotherapy

Serious events: 28 serious events

Other events: 100 other events

Deaths: 5 deaths

After Switch: Any Upadacitinib 15 mg

Serious events: 35 serious events

Other events: 126 other events

Deaths: 7 deaths

Serious adverse events

Measure	Weeks 1-24: Methotrexate Monotherapy n=314 participants at risk Participants received up to 20 mg methotrexate orally per week (15 mg/week in China and Japan) and placebo to upadacitinib QD for 24 weeks during Period 1.	Weeks 1-24: Upadacitinib 7.5 mg Monotherapy n=55 participants at risk Participants received 7.5 mg upadacitinib orally once a day and placebo to methotrexate once a week for 24 weeks in Period 1.	Weeks 1-24: Upadacitinib 15 mg Monotherapy n=317 participants at risk Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 24 weeks in Period 1.	Weeks 1-24: Upadacitinib 30 mg Monotherapy n=314 participants at risk Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 24 weeks in Period 1.	Weeks 1-260: Methotrexate Monotherapy n=314 participants at risk Participants received up to 20 mg methotrexate orally per week (15 mg/week in China and Japan) for 260 weeks. Includes events up until the addition of upadacitinib for participants who were rescued at Week 26.	Weeks 1-260: Upadacitinib 7.5 mg Monotherapy n=55 participants at risk Participants received 7.5 mg upadacitinib monotherapy once a day for 260 weeks. Includes events up until the addition of methotrexate or addition of background conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) for participants who received rescue.	Weeks 1-260: Upadacitinib 15 mg Monotherapy n=317 participants at risk Participants received 15 mg upadacitinib monotherapy once a day for 260 weeks. Includes events up until the addition of methotrexate or addition of background csDMARD for participants who received rescue.	Weeks 1-260/Switch: Upadacitinib 30 mg Monotherapy n=314 participants at risk Participants received 30 mg upadacitinib monotherapy once a day for 260 weeks or until implementation of Protocol Amendment 6 (December 2019) when they were switched to upadacitinib 15 mg. Includes events up until the addition of methotrexate or addition of background csDMARD for participants who received rescue, or up until the switch to upadacitinib 15 mg.	Weeks 1-260: Any Upadacitinib 7.5 mg n=56 participants at risk Participants originally randomized to upadacitinib 7.5 mg received upadacitinib 7.5 mg QD for up to 260 weeks, including events after the addition of rescue therapy. Participants originally randomized to methotrexate and rescued at Week 26 to methotrexate plus upadacitinib 7.5 mg received upadacitinib 7.5 mg QD from Week 26 to Week 260.	Weeks 1-260: Any Upadacitinib 15 mg n=335 participants at risk Participants originally randomized to upadacitinib 15 mg received upadacitinib 15 mg QD for up to 260 weeks, including events after the addition of rescue therapy. Participants originally randomized to methotrexate and rescued at Week 26 to methotrexate plus upadacitinib 15 mg received upadacitinib 15 mg QD from Week 26 to Week 260.	Weeks 1-260/Switch: Any Upadacitinib 30 mg n=332 participants at risk Participants originally randomized to upadacitinib 30 mg received upadacitinib 30 mg QD for up to 260 weeks or until implementation of Protocol Amendment 6 (December 2019) when they were switched to upadacitinib 15 mg, including events after the addition of rescue therapy. Participants originally randomized to methotrexate and rescued at Week 26 to methotrexate plus upadacitinib 30 mg received upadacitinib 30 mg QD from Week 26 to Week 260 or until implementation of Protocol Amendment 6 when they were switched to methotrexate plus upadacitinib 15 mg. Includes events up until the switch to upadacitinib 15 mg.	After Switch: Upadacitinib 15 mg Monotherapy n=181 participants at risk Participants who were receiving upadacitinib 30 mg QD monotherapy in Period 2 were switched to receive upadacitinib 15 mg QD monotherapy after implementation of Protocol Amendment 6 (December 2019) up to Week 260.	After Switch: Any Upadacitinib 15 mg n=218 participants at risk Participants who were receiving any upadacitinib 30 mg QD (monotherapy or in combination with methotrexate or csDMARD after rescue) in Period 2 were switched to receive upadacitinib 15 mg QD (monotherapy or in combination with methotrexate or csDMARD if rescued) after implementation of Protocol Amendment 6 (December 2019) up to Week 260.
Blood and lymphatic system disorders ANAEMIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Blood and lymphatic system disorders IRON DEFICIENCY ANAEMIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders ACUTE CORONARY SYNDROME	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders ACUTE MYOCARDIAL INFARCTION	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders ANGINA PECTORIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders ARTERIOSPASM CORONARY	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders ATRIAL FIBRILLATION	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders CARDIAC ARREST	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders CARDIAC FAILURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders CARDIAC FAILURE CONGESTIVE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders CARDIAC TAMPONADE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders CARDIO-RESPIRATORY ARREST	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders CARDIOVASCULAR DISORDER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders METABOLIC CARDIOMYOPATHY	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders MYOCARDIAL FIBROSIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders MYOCARDIAL INFARCTION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders MYOCARDIAL ISCHAEMIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders PERICARDITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders SINUS NODE DYSFUNCTION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders SUPRAVENTRICULAR TACHYCARDIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Cardiac disorders TACHYCARDIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Congenital, familial and genetic disorders HAEMORRHAGIC ARTERIOVENOUS MALFORMATION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Eye disorders CATARACT	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Eye disorders CATARACT DIABETIC	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Eye disorders IRIDOCYCLITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Eye disorders MACULAR HOLE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Eye disorders VITREORETINAL TRACTION SYNDROME	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Eye disorders VITREOUS HAEMORRHAGE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders ABDOMINAL PAIN	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders ABDOMINAL WALL HAEMATOMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders ANAL FISTULA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders ASCITES	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders COLITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders CONSTIPATION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders DIVERTICULAR PERFORATION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders DUODENAL ULCER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders FOOD POISONING	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders GASTRIC ULCER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders GASTRIC ULCER HAEMORRHAGE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders GASTRIC ULCER PERFORATION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders GASTRITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders GASTROINTESTINAL HAEMORRHAGE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders GINGIVAL RECESSION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders HIATUS HERNIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders INCARCERATED INGUINAL HERNIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders INGUINAL HERNIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders LARGE INTESTINE PERFORATION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders LARGE INTESTINE POLYP	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders PANCREATIC DISORDER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders PANCREATITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders RECTAL HAEMORRHAGE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders RECTAL POLYP	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders SALIVARY GLAND CALCULUS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
General disorders CHEST DISCOMFORT	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
General disorders CHEST PAIN	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
General disorders DEATH	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
General disorders MULTIPLE ORGAN DYSFUNCTION SYNDROME	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
General disorders SUDDEN DEATH	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Hepatobiliary disorders BILE DUCT STONE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Hepatobiliary disorders CHOLANGITIS	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Hepatobiliary disorders CHOLECYSTITIS ACUTE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Hepatobiliary disorders CHOLELITHIASIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.2% 4/332 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Hepatobiliary disorders GALLBLADDER RUPTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations ACTINOMYCOTIC PULMONARY INFECTION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations APPENDICITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations BACTERIAL PYELONEPHRITIS	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations BRONCHITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations BRONCHOPULMONARY ASPERGILLOSIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations COVID-19	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.1% 2/181 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.4% 3/218 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations COVID-19 PNEUMONIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/335 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.4% 8/181 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 12/218 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations CELLULITIS	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations CORONAVIRUS PNEUMONIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations DIVERTICULITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations EMPYEMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations ENDOCARDITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations ERYSIPELAS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations ESCHERICHIA INFECTION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations FEMALE GENITAL TRACT TUBERCULOSIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations GALLBLADDER ABSCESS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations GASTROENTERITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations GENITAL HERPES SIMPLEX	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations HERPES ZOSTER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/332 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations HERPES ZOSTER DISSEMINATED	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations HERPES ZOSTER MENINGITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations INFECTIVE SPONDYLITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations INFLUENZA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations KERATITIS BACTERIAL	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations LUNG ABSCESS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations MENINGITIS BACTERIAL	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations NECROTISING FASCIITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations OPHTHALMIC HERPES ZOSTER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations OSTEOMYELITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PARAINFLUENZAE VIRUS INFECTION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PERITONEAL TUBERCULOSIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PERITONITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PNEUMONIA	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/317 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/314 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.7% 9/335 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.5% 5/332 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.92% 2/218 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PNEUMONIA BACTERIAL	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PNEUMONIA CRYPTOCOCCAL	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PNEUMONIA ESCHERICHIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PNEUMONIA KLEBSIELLA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PNEUMONIA PNEUMOCOCCAL	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PROSTATITIS ESCHERICHIA COLI	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PYELONEPHRITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PYELONEPHRITIS ACUTE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/56 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PYELONEPHRITIS CHRONIC	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations Q FEVER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations RESPIRATORY TRACT INFECTION VIRAL	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations SEPSIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations SEPTIC SHOCK	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations SINOBRONCHITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations STAPHYLOCOCCAL INFECTION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations SUBCUTANEOUS ABSCESS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations TOOTH ABSCESS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations UPPER RESPIRATORY TRACT INFECTION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations URINARY TRACT INFECTION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications ANKLE FRACTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications CONCUSSION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications CONTUSION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications CORNEAL LACERATION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications FEMORAL NECK FRACTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications FEMUR FRACTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications FOOT FRACTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications HIP FRACTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications HUMERUS FRACTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications JOINT DISLOCATION	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications LIMB CRUSHING INJURY	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications LOWER LIMB FRACTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications MENISCUS INJURY	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications PATELLA FRACTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications POST LUMBAR PUNCTURE SYNDROME	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications POST PROCEDURAL FISTULA	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications RADIUS FRACTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications ROAD TRAFFIC ACCIDENT	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications SUBDURAL HAEMATOMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications TENDON RUPTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications THORACIC VERTEBRAL FRACTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications UPPER LIMB FRACTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications WRIST FRACTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Investigations BLOOD CREATINE PHOSPHOKINASE INCREASED	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Investigations HEPATIC ENZYME INCREASED	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Investigations TRANSAMINASES INCREASED	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Investigations WHITE BLOOD CELL COUNT INCREASED	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Metabolism and nutrition disorders ABNORMAL WEIGHT GAIN	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Metabolism and nutrition disorders CENTRAL OBESITY	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Metabolism and nutrition disorders DEHYDRATION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Metabolism and nutrition disorders DIABETIC KETOACIDOSIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Metabolism and nutrition disorders HYPOKALAEMIA	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Metabolism and nutrition disorders OBESITY	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders ACQUIRED CLAW TOE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders BURSITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders INTERVERTEBRAL DISC PROTRUSION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders LUMBAR SPINAL STENOSIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders NECK PAIN	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders OSTEOARTHRITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.95% 3/317 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.2% 4/335 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/332 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders OSTEONECROSIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders PAIN IN EXTREMITY	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders PATHOLOGICAL FRACTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders ROTATOR CUFF SYNDROME	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders SPONDYLOLISTHESIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders SUBCHONDRAL INSUFFICIENCY FRACTURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders SYMPATHETIC POSTERIOR CERVICAL SYNDROME	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders SYSTEMIC LUPUS ERYTHEMATOSUS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ADENOCARCINOMA GASTRIC	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ADENOCARCINOMA METASTATIC	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ADENOCARCINOMA OF COLON	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ANGIOFIBROMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) B-CELL LYMPHOMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BASAL CELL CARCINOMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BENIGN OVARIAN TUMOUR	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BLADDER CANCER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BLADDER NEOPLASM	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BOWEN'S DISEASE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BREAST CANCER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BREAST CANCER METASTATIC	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) CERVIX CARCINOMA STAGE 0	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ENDOMETRIAL ADENOCARCINOMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) FIBROMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) GASTRIC CANCER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LEIOMYOMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LIPOMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG ADENOCARCINOMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG SQUAMOUS CELL CARCINOMA METASTATIC	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) MALIGNANT MELANOMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) MALIGNANT PALATE NEOPLASM	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTASES TO BONE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTATIC NEOPLASM	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) NEUROENDOCRINE TUMOUR	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) NON-SMALL CELL LUNG CANCER METASTATIC	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) OVARIAN CANCER	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) OVARIAN GERM CELL TERATOMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) PAPILLARY THYROID CANCER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) PROSTATE CANCER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) RENAL CANCER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) RENAL CELL CARCINOMA STAGE I	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SEBACEOUS CARCINOMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SQUAMOUS CELL CARCINOMA OF LUNG	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SQUAMOUS CELL CARCINOMA OF SKIN	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SQUAMOUS CELL CARCINOMA OF THE TONGUE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) UTERINE CANCER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) UTERINE CARCINOMA IN SITU	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Nervous system disorders CAROTID ARTERIOSCLEROSIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Nervous system disorders CAROTID ARTERY DISEASE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Nervous system disorders HYPOXIC-ISCHAEMIC ENCEPHALOPATHY	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Nervous system disorders MONOPARESIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Nervous system disorders MYELOPATHY	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Nervous system disorders SCIATICA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Nervous system disorders SPONDYLITIC MYELOPATHY	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Nervous system disorders SYNCOPE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Nervous system disorders TRANSIENT ISCHAEMIC ATTACK	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.95% 3/317 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/335 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Nervous system disorders VERTEBROBASILAR INSUFFICIENCY	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Pregnancy, puerperium and perinatal conditions ABORTION SPONTANEOUS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Product Issues DEVICE DISLOCATION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Psychiatric disorders DEPRESSION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Psychiatric disorders MENTAL DISORDER DUE TO A GENERAL MEDICAL CONDITION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Renal and urinary disorders ACUTE KIDNEY INJURY	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Renal and urinary disorders NEPHROLITHIASIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Renal and urinary disorders RENAL COLIC	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Renal and urinary disorders RENAL CYST	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Renal and urinary disorders RENAL FAILURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Renal and urinary disorders URETEROLITHIASIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Reproductive system and breast disorders BENIGN PROSTATIC HYPERPLASIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Reproductive system and breast disorders BREAST HYPOPLASIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Reproductive system and breast disorders CERVICAL DYSPLASIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Reproductive system and breast disorders CERVIX HAEMORRHAGE UTERINE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Reproductive system and breast disorders ENDOMETRIAL HYPERPLASIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Reproductive system and breast disorders MENOMETRORRHAGIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Reproductive system and breast disorders OVARIAN CYST	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Reproductive system and breast disorders OVARIAN CYST RUPTURED	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Reproductive system and breast disorders PROSTATITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Respiratory, thoracic and mediastinal disorders ACUTE RESPIRATORY FAILURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Respiratory, thoracic and mediastinal disorders ASTHMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Respiratory, thoracic and mediastinal disorders ASTHMATIC CRISIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Respiratory, thoracic and mediastinal disorders CHRONIC OBSTRUCTIVE PULMONARY DISEASE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Respiratory, thoracic and mediastinal disorders PLEURAL EFFUSION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Respiratory, thoracic and mediastinal disorders PLEURISY	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Respiratory, thoracic and mediastinal disorders PNEUMOTHORAX	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Respiratory, thoracic and mediastinal disorders PNEUMOTHORAX SPONTANEOUS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Respiratory, thoracic and mediastinal disorders PULMONARY EMBOLISM	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/332 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Respiratory, thoracic and mediastinal disorders PULMONARY FIBROSIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Respiratory, thoracic and mediastinal disorders RESPIRATORY FAILURE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Skin and subcutaneous tissue disorders ANGIOEDEMA	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Skin and subcutaneous tissue disorders DIABETIC FOOT	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Skin and subcutaneous tissue disorders DRUG ERUPTION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Skin and subcutaneous tissue disorders SKIN ULCER	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Vascular disorders DEEP VEIN THROMBOSIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Vascular disorders EMBOLISM ARTERIAL	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Vascular disorders HYPERTENSION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Vascular disorders PERIPHERAL ARTERIAL OCCLUSIVE DISEASE	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Vascular disorders PERIPHERAL ARTERY STENOSIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Vascular disorders PERIPHERAL ISCHAEMIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Vascular disorders SHOCK HAEMORRHAGIC	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.

Other adverse events

Measure	Weeks 1-24: Methotrexate Monotherapy n=314 participants at risk Participants received up to 20 mg methotrexate orally per week (15 mg/week in China and Japan) and placebo to upadacitinib QD for 24 weeks during Period 1.	Weeks 1-24: Upadacitinib 7.5 mg Monotherapy n=55 participants at risk Participants received 7.5 mg upadacitinib orally once a day and placebo to methotrexate once a week for 24 weeks in Period 1.	Weeks 1-24: Upadacitinib 15 mg Monotherapy n=317 participants at risk Participants received 15 mg upadacitinib orally once a day and placebo to methotrexate once a week for 24 weeks in Period 1.	Weeks 1-24: Upadacitinib 30 mg Monotherapy n=314 participants at risk Participants received 30 mg upadacitinib orally once a day and placebo to methotrexate once a week for 24 weeks in Period 1.	Weeks 1-260: Methotrexate Monotherapy n=314 participants at risk Participants received up to 20 mg methotrexate orally per week (15 mg/week in China and Japan) for 260 weeks. Includes events up until the addition of upadacitinib for participants who were rescued at Week 26.	Weeks 1-260: Upadacitinib 7.5 mg Monotherapy n=55 participants at risk Participants received 7.5 mg upadacitinib monotherapy once a day for 260 weeks. Includes events up until the addition of methotrexate or addition of background conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) for participants who received rescue.	Weeks 1-260: Upadacitinib 15 mg Monotherapy n=317 participants at risk Participants received 15 mg upadacitinib monotherapy once a day for 260 weeks. Includes events up until the addition of methotrexate or addition of background csDMARD for participants who received rescue.	Weeks 1-260/Switch: Upadacitinib 30 mg Monotherapy n=314 participants at risk Participants received 30 mg upadacitinib monotherapy once a day for 260 weeks or until implementation of Protocol Amendment 6 (December 2019) when they were switched to upadacitinib 15 mg. Includes events up until the addition of methotrexate or addition of background csDMARD for participants who received rescue, or up until the switch to upadacitinib 15 mg.	Weeks 1-260: Any Upadacitinib 7.5 mg n=56 participants at risk Participants originally randomized to upadacitinib 7.5 mg received upadacitinib 7.5 mg QD for up to 260 weeks, including events after the addition of rescue therapy. Participants originally randomized to methotrexate and rescued at Week 26 to methotrexate plus upadacitinib 7.5 mg received upadacitinib 7.5 mg QD from Week 26 to Week 260.	Weeks 1-260: Any Upadacitinib 15 mg n=335 participants at risk Participants originally randomized to upadacitinib 15 mg received upadacitinib 15 mg QD for up to 260 weeks, including events after the addition of rescue therapy. Participants originally randomized to methotrexate and rescued at Week 26 to methotrexate plus upadacitinib 15 mg received upadacitinib 15 mg QD from Week 26 to Week 260.	Weeks 1-260/Switch: Any Upadacitinib 30 mg n=332 participants at risk Participants originally randomized to upadacitinib 30 mg received upadacitinib 30 mg QD for up to 260 weeks or until implementation of Protocol Amendment 6 (December 2019) when they were switched to upadacitinib 15 mg, including events after the addition of rescue therapy. Participants originally randomized to methotrexate and rescued at Week 26 to methotrexate plus upadacitinib 30 mg received upadacitinib 30 mg QD from Week 26 to Week 260 or until implementation of Protocol Amendment 6 when they were switched to methotrexate plus upadacitinib 15 mg. Includes events up until the switch to upadacitinib 15 mg.	After Switch: Upadacitinib 15 mg Monotherapy n=181 participants at risk Participants who were receiving upadacitinib 30 mg QD monotherapy in Period 2 were switched to receive upadacitinib 15 mg QD monotherapy after implementation of Protocol Amendment 6 (December 2019) up to Week 260.	After Switch: Any Upadacitinib 15 mg n=218 participants at risk Participants who were receiving any upadacitinib 30 mg QD (monotherapy or in combination with methotrexate or csDMARD after rescue) in Period 2 were switched to receive upadacitinib 15 mg QD (monotherapy or in combination with methotrexate or csDMARD if rescued) after implementation of Protocol Amendment 6 (December 2019) up to Week 260.
Blood and lymphatic system disorders ANAEMIA	1.6% 5/314 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/317 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.9% 9/314 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 17/314 • Number of events 19 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.3% 20/317 • Number of events 31 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.1% 16/314 • Number of events 21 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.9% 5/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.6% 22/335 • Number of events 34 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 18/332 • Number of events 24 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 4/181 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.2% 7/218 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Blood and lymphatic system disorders LEUKOPENIA	1.3% 4/314 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/317 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.1% 13/314 • Number of events 23 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.8% 9/317 • Number of events 19 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.8% 15/314 • Number of events 25 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/56 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.3% 11/335 • Number of events 24 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 18/332 • Number of events 39 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 10/181 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.6% 10/218 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Blood and lymphatic system disorders NEUTROPENIA	0.64% 2/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/317 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.9% 9/314 • Number of events 11 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.5% 11/314 • Number of events 15 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.1% 13/317 • Number of events 26 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.0% 25/314 • Number of events 37 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.5% 15/335 • Number of events 32 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.1% 27/332 • Number of events 56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.4% 8/181 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.1% 9/218 • Number of events 11 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Eye disorders CATARACT	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.95% 3/317 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.5% 5/335 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/332 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.1% 2/181 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.92% 2/218 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Eye disorders DRY EYE	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/335 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/332 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders CHRONIC GASTRITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.9% 5/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/332 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders CONSTIPATION	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.1% 13/314 • Number of events 13 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.8% 12/317 • Number of events 13 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.7% 18/314 • Number of events 21 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	10.7% 6/56 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.9% 13/335 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.0% 20/332 • Number of events 23 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders DENTAL CARIES	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/317 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.1% 4/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.5% 5/335 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.2% 4/332 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders DIARRHOEA	3.2% 10/314 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.5% 11/317 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.1% 16/314 • Number of events 16 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.9% 25/317 • Number of events 33 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.1% 19/314 • Number of events 26 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.1% 27/335 • Number of events 36 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.3% 21/332 • Number of events 28 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.7% 3/181 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.4% 3/218 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders DYSPEPSIA	3.8% 12/314 • Number of events 13 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/317 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.4% 20/314 • Number of events 29 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.8% 12/317 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.9% 13/335 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 6/332 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders GASTROOESOPHAGEAL REFLUX DISEASE	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/317 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.9% 9/314 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/317 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.9% 9/314 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.9% 5/56 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.4% 8/335 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.0% 10/332 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders HAEMORRHOIDS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/317 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.2% 4/335 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.2% 4/332 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders NAUSEA	5.4% 17/314 • Number of events 29 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.7% 18/317 • Number of events 20 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.8% 12/314 • Number of events 13 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.2% 29/314 • Number of events 47 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.9% 25/317 • Number of events 28 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 17/314 • Number of events 19 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.1% 4/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.5% 25/335 • Number of events 30 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.7% 19/332 • Number of events 22 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.4% 3/218 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Gastrointestinal disorders STOMATITIS	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	14.5% 8/55 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/317 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	14.3% 8/56 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.2% 4/335 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/332 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
General disorders FATIGUE	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/317 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.0% 16/317 • Number of events 20 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.8% 16/335 • Number of events 21 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/332 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
General disorders INFLUENZA LIKE ILLNESS	2.5% 8/314 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/317 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.8% 15/314 • Number of events 20 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 17/317 • Number of events 19 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.5% 14/314 • Number of events 15 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.3% 21/335 • Number of events 24 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 18/332 • Number of events 21 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
General disorders PYREXIA	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/314 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.1% 5/55 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.8% 9/317 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.9% 9/314 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	12.5% 7/56 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.3% 11/335 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.7% 9/332 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.1% 2/181 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.4% 3/218 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Hepatobiliary disorders HEPATIC STEATOSIS	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/314 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/317 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.4% 8/335 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.1% 7/332 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.8% 5/181 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.3% 5/218 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations BRONCHITIS	1.9% 6/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/317 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.6% 24/314 • Number of events 27 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	12.7% 7/55 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.9% 22/317 • Number of events 26 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.6% 27/314 • Number of events 38 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	16.1% 9/56 • Number of events 11 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.9% 33/335 • Number of events 37 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.7% 29/332 • Number of events 40 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.8% 5/181 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.2% 7/218 • Number of events 11 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations COVID-19	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.7% 18/314 • Number of events 20 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.8% 28/317 • Number of events 28 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.1% 4/56 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	11.0% 37/335 • Number of events 38 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.2% 4/332 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	10.5% 19/181 • Number of events 20 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	10.1% 22/218 • Number of events 23 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations CONJUNCTIVITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/317 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.1% 4/56 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.7% 9/335 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.2% 4/332 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations CYSTITIS	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.1% 5/55 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/317 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.9% 9/314 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	10.7% 6/56 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.4% 8/335 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.3% 11/332 • Number of events 11 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.8% 5/181 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.3% 5/218 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations GASTROENTERITIS	2.2% 7/314 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/317 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/314 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.8% 12/314 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	14.5% 8/55 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.5% 11/317 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.2% 10/314 • Number of events 11 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	16.1% 9/56 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.9% 13/335 • Number of events 17 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.0% 10/332 • Number of events 11 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations HERPES ZOSTER	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/317 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/314 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/314 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	21.8% 12/55 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	10.1% 32/317 • Number of events 38 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.6% 24/314 • Number of events 26 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	23.2% 13/56 • Number of events 13 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	10.1% 34/335 • Number of events 42 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.1% 27/332 • Number of events 29 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.9% 7/181 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.7% 8/218 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations INFLUENZA	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/314 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	14.5% 8/55 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/317 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.9% 9/314 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	17.9% 10/56 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.7% 9/335 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.3% 11/332 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.1% 2/181 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.92% 2/218 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations LATENT TUBERCULOSIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.5% 14/314 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.5% 11/317 • Number of events 11 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.8% 15/314 • Number of events 15 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.2% 14/335 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 18/332 • Number of events 18 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.1% 2/181 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.4% 3/218 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations NASOPHARYNGITIS	4.1% 13/314 • Number of events 15 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.1% 5/55 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.7% 18/317 • Number of events 22 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 17/314 • Number of events 18 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	13.7% 43/314 • Number of events 70 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	40.0% 22/55 • Number of events 49 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	15.1% 48/317 • Number of events 87 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	16.2% 51/314 • Number of events 72 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	44.6% 25/56 • Number of events 59 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	17.0% 57/335 • Number of events 99 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	17.5% 58/332 • Number of events 79 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.4% 8/181 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.6% 10/218 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations ORAL CANDIDIASIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/317 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.1% 4/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.5% 5/335 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations ORAL HERPES	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/317 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/314 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	12.7% 7/55 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.0% 16/317 • Number of events 21 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.5% 11/314 • Number of events 13 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	14.3% 8/56 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.1% 17/335 • Number of events 22 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.9% 13/332 • Number of events 16 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PERIODONTITIS	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/317 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.9% 5/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.2% 4/335 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/332 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations PHARYNGITIS	1.9% 6/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.1% 5/55 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/317 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/314 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.1% 16/314 • Number of events 20 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	21.8% 12/55 • Number of events 22 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.8% 12/317 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 17/314 • Number of events 22 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	23.2% 13/56 • Number of events 24 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.2% 14/335 • Number of events 18 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 18/332 • Number of events 23 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.7% 3/181 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 4/218 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations SINUSITIS	1.9% 6/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/317 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.5% 11/314 • Number of events 19 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.4% 14/317 • Number of events 27 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/314 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.8% 16/335 • Number of events 29 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.4% 8/332 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.1% 2/181 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.4% 3/218 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations TINEA PEDIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/317 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 6/335 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/332 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.1% 2/181 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.92% 2/218 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations UPPER RESPIRATORY TRACT INFECTION	4.5% 14/314 • Number of events 17 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.3% 20/317 • Number of events 23 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 23/314 • Number of events 28 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.9% 31/314 • Number of events 45 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	16.4% 9/55 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	15.5% 49/317 • Number of events 88 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	13.7% 43/314 • Number of events 72 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	16.1% 9/56 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	17.6% 59/335 • Number of events 102 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	15.4% 51/332 • Number of events 87 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.8% 5/181 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.2% 7/218 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Infections and infestations URINARY TRACT INFECTION	6.4% 20/314 • Number of events 24 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 17/317 • Number of events 19 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.7% 18/314 • Number of events 21 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	13.1% 41/314 • Number of events 59 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	13.6% 43/317 • Number of events 93 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	12.1% 38/314 • Number of events 64 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	15.2% 51/335 • Number of events 107 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	13.6% 45/332 • Number of events 76 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.2% 13/181 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.7% 19/218 • Number of events 21 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications CONTUSION	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/314 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	14.5% 8/55 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.2% 10/317 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	17.9% 10/56 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.3% 11/335 • Number of events 11 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.5% 5/332 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.7% 3/181 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.3% 5/218 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Injury, poisoning and procedural complications SPINAL COMPRESSION FRACTURE	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.95% 3/317 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/335 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Investigations ALANINE AMINOTRANSFERASE INCREASED	3.8% 12/314 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.0% 16/317 • Number of events 21 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/314 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.9% 28/314 • Number of events 34 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.5% 27/317 • Number of events 49 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.9% 28/314 • Number of events 48 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.1% 4/56 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.6% 32/335 • Number of events 58 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.6% 32/332 • Number of events 52 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.7% 3/181 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 4/218 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Investigations ASPARTATE AMINOTRANSFERASE INCREASED	2.5% 8/314 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.2% 10/317 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/314 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 23/314 • Number of events 27 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.6% 21/317 • Number of events 31 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.6% 24/314 • Number of events 33 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/56 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.2% 24/335 • Number of events 35 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.1% 27/332 • Number of events 36 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.1% 2/181 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.4% 3/218 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Investigations BLOOD CREATINE PHOSPHOKINASE INCREASED	0.64% 2/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.8% 9/317 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	10.8% 34/314 • Number of events 39 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.2% 10/314 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	11.7% 37/317 • Number of events 68 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	16.2% 51/314 • Number of events 106 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.9% 5/56 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	13.7% 46/335 • Number of events 79 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	16.3% 54/332 • Number of events 110 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 10/181 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 12/218 • Number of events 17 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Investigations BLOOD CREATININE INCREASED	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/314 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/317 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/314 • Number of events 13 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.7% 9/335 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.7% 9/332 • Number of events 15 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Investigations LIVER FUNCTION TEST INCREASED	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/335 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Investigations LYMPHOCYTE COUNT DECREASED	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/332 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Investigations NEUTROPHIL COUNT DECREASED	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.95% 3/317 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/317 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.5% 5/335 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.2% 4/332 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.1% 2/181 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.4% 3/218 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Investigations WEIGHT INCREASED	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/317 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/314 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.7% 15/317 • Number of events 17 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/314 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.1% 17/335 • Number of events 19 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.1% 7/332 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Investigations WHITE BLOOD CELL COUNT DECREASED	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/314 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.1% 7/332 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Metabolism and nutrition disorders DYSLIPIDAEMIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.95% 3/317 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.1% 5/55 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.7% 15/317 • Number of events 17 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.8% 15/314 • Number of events 17 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.9% 5/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.1% 17/335 • Number of events 22 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.5% 15/332 • Number of events 18 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.1% 2/181 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.92% 2/218 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Metabolism and nutrition disorders HYPERCHOLESTEROLAEMIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/317 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/314 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 17/317 • Number of events 23 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.5% 14/314 • Number of events 19 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/56 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.7% 19/335 • Number of events 27 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.8% 16/332 • Number of events 21 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.7% 3/181 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.4% 3/218 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Metabolism and nutrition disorders HYPERLIPIDAEMIA	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/317 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/317 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.1% 4/56 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.4% 8/335 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.4% 8/332 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.92% 2/218 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Metabolism and nutrition disorders HYPERTRIGLYCERIDAEMIA	2.5% 8/314 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.5% 11/317 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/314 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.2% 10/314 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.6% 21/317 • Number of events 31 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.1% 19/314 • Number of events 31 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/56 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.6% 22/335 • Number of events 33 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.3% 21/332 • Number of events 33 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 4/181 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.3% 5/218 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders ARTHRALGIA	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/317 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.1% 13/314 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.3% 20/317 • Number of events 31 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.1% 16/314 • Number of events 19 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.8% 26/335 • Number of events 40 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.1% 17/332 • Number of events 22 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.7% 3/181 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.8% 6/218 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders BACK PAIN	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/317 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.2% 10/314 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	10.9% 6/55 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.3% 20/317 • Number of events 20 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.4% 20/314 • Number of events 27 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	10.7% 6/56 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.5% 25/335 • Number of events 27 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.9% 23/332 • Number of events 30 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.3% 6/181 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.2% 7/218 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders INTERVERTEBRAL DISC PROTRUSION	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/317 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 6/335 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders MYALGIA	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.95% 3/317 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/314 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/317 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.1% 4/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.1% 7/335 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.5% 5/332 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders OSTEOPOROSIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/317 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/314 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 6/335 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.4% 8/332 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.4% 3/218 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders PERIARTHRITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/335 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Musculoskeletal and connective tissue disorders RHEUMATOID ARTHRITIS	6.1% 19/314 • Number of events 20 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/317 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	14.0% 44/314 • Number of events 65 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.1% 29/317 • Number of events 37 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.5% 11/314 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.9% 5/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	11.6% 39/335 • Number of events 57 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 12/332 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.4% 17/181 • Number of events 19 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	11.5% 25/218 • Number of events 31 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Nervous system disorders DIZZINESS	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/317 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/314 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/317 • Number of events 11 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/314 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.1% 4/56 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.7% 9/335 • Number of events 13 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.4% 8/332 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.92% 2/218 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Nervous system disorders HEADACHE	1.9% 6/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.2% 7/317 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.5% 14/314 • Number of events 16 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 17/314 • Number of events 19 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.8% 12/317 • Number of events 13 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.7% 21/314 • Number of events 26 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.1% 4/56 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 18/335 • Number of events 20 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.4% 28/332 • Number of events 33 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.1% 2/181 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 4/218 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Nervous system disorders POST HERPETIC NEURALGIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.3% 4/55 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.9% 5/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.2% 4/335 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Psychiatric disorders INSOMNIA	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.95% 3/317 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.9% 9/314 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.0% 16/317 • Number of events 18 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/56 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.1% 17/335 • Number of events 19 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.5% 5/332 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Renal and urinary disorders POLLAKIURIA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/332 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Respiratory, thoracic and mediastinal disorders ASTHMA	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/335 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Respiratory, thoracic and mediastinal disorders COUGH	1.6% 5/314 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.2% 10/317 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.2% 10/314 • Number of events 11 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.8% 15/314 • Number of events 15 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	7.6% 24/317 • Number of events 28 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.1% 19/314 • Number of events 23 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/56 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.7% 29/335 • Number of events 35 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	6.6% 22/332 • Number of events 26 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.7% 3/181 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.4% 3/218 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Respiratory, thoracic and mediastinal disorders RHINITIS ALLERGIC	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/317 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.63% 2/317 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.2% 4/335 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.90% 3/332 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Skin and subcutaneous tissue disorders DERMATITIS	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/317 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.2% 4/335 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.60% 2/332 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Skin and subcutaneous tissue disorders DRY SKIN	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/314 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/335 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.30% 1/332 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/181 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/218 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Skin and subcutaneous tissue disorders ECZEMA	0.32% 1/314 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.6% 2/55 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.32% 1/317 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.96% 3/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.1% 5/55 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/317 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/314 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.9% 5/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.4% 8/335 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 6/332 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.7% 3/181 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.4% 3/218 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Skin and subcutaneous tissue disorders PRURITUS	0.96% 3/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.00% 0/55 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.95% 3/317 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.64% 2/314 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.9% 6/317 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/314 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.4% 3/56 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 6/335 • Number of events 7 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.5% 5/332 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.55% 1/181 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.46% 1/218 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Skin and subcutaneous tissue disorders RASH	1.6% 5/314 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.8% 1/55 • Number of events 1 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.6% 5/317 • Number of events 6 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.3% 4/314 • Number of events 4 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.9% 9/314 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.1% 5/55 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.5% 8/317 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.5% 11/314 • Number of events 13 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	8.9% 5/56 • Number of events 5 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	2.7% 9/335 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.9% 13/332 • Number of events 17 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	1.1% 2/181 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	0.92% 2/218 • Number of events 2 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.
Vascular disorders HYPERTENSION	2.5% 8/314 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	5.5% 3/55 • Number of events 3 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	3.8% 12/317 • Number of events 12 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.5% 14/314 • Number of events 14 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	9.9% 31/314 • Number of events 34 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	14.5% 8/55 • Number of events 9 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	11.4% 36/317 • Number of events 40 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	14.0% 44/314 • Number of events 46 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	16.1% 9/56 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	12.8% 43/335 • Number of events 48 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	14.2% 47/332 • Number of events 51 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.4% 8/181 • Number of events 8 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.	4.6% 10/218 • Number of events 10 • From first dose of study drug up to 30 days after last dose, maximum of 264 weeks; Adverse events (AEs) are reported for Weeks 1 to 24, Weeks 1 to 260, and After Switch for participants who transitioned from upadacitinib 30 mg QD to 15 mg QD after implementation of Protocol Amendment 6 in December 2019. In Weeks 1 to 24 all participants received monotherapy. For Weeks 1 to 260 and After Switch, AEs are reported for the following: * Monotherapy: includes participants receiving monotherapy until the end of study or until rescue treatment was initiated. * All upadacitinib: includes any exposure to upadacitinib, alone or in addition to methotrexate or csDMARD after rescue, including participants originally assigned to methotrexate who were rescued with methotrexate + upadacitinib at Week 26.

Additional Information

Global Medical Services

AbbVie

Phone: 800-633-9110

Email: abbvieclinicaltrials@abbvie.com

Results disclosure agreements

• Principal investigator is a sponsor employee AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.
• Publication restrictions are in place

Restriction type: OTHER